Phase 2 Basket Study Evaluating BAY2927088 in HER2-Activated Solid Tumors

Bayer is assessing BAY2927088—an oral EGFR and HER2 inhibitor—in adults with metastatic or unresectable solid tumors harboring HER2-activating mutations, including colorectal, biliary, bladder, cervical, and endometrial cancers. Participants will receive 20 mg BID in 3‑week cycles until disease progression or unacceptable toxicity.